These findings led to a somehow improved tumor/background ratios for 111In-PSMAI&T compared to 177Lu-PSMA-I&T at 1 h p.i. (tumor/blood-, tumor/liver-, tumor/intestines-, and tumor/muscle-ratios of 34 ± 8, 32 ± 6, 53 ± 8, and 43 ± 6, respectively, versus 18 ± 9, 7 ± 3, 12 ± 3, and 14 ± 9 for 177Lu-PSMA-I&T) [135,142]. The gene discussed is FOLH1; the disease is neoplasm.